COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,702 Articles (22,913 medRxiv, 8,789 bioRxiv)

Most recent first Previous |  Page 1447: Articles 14461-14470  | Next

SARS-CoV-2 environmental contamination from hospitalised COVID-19 patients receiving aerosol generating procedures
Winslow, R., Zhou, J., Windle, E. F., Nur, I. X., Lall, R., Millar, J. E., Dark, P. M., Naisbitt, J., Simonds, A., Dunning, J., Barclay, W., Baillie, J. K., Perkins, G. D., Semple, M. G., McAuley, D. F., Green, C. A.
10.1101/2021.07.04.21259945 — Posted: 2021-07-05
Angiotensin II receptor I auto-antibodies following SARS-CoV-2 infection
Harrington, W. E., Jiang, Y., Duffy, F., Hadlock, J., Raappana, A., Styrchak, S., Beck, I., Chour, W., Houck, J., Duvvuri, V., Yeung, W., Haglund, M., Wallner, J., Wallick, J., Hardy, S., Oldroyd, A., Ko, D., Gervassi, A., Murray, K., Kaplan, H., Aitchison, J., Heath, J., Sather, D. N., Goldman, J., Frenkel, L.
10.1101/2021.06.30.21259796 — Posted: 2021-07-05
Low dose mRNA-1273 COVID-19 vaccine generates durable T cell memory and antibodies enhanced by pre-existing crossreactive T cell memory
Mateus, J., Dan, J. M., Zhang, Z., Rydyznski Moderbacher, C., Lammers, M., Goodwin, B., Sette, A., Crotty, S., Weiskopf, D.
10.1101/2021.06.30.21259787 — Posted: 2021-07-05 Discussion: Onsite
Reduced COVID-19 Hospitalizations among New York City Residents Following Age-Based SARS-CoV-2 Vaccine Eligibility: Evidence from a Regression Discontinuity Design
Greene, S. K., Levin-Rector, A., McGibbon, E., Baumgartner, J., Devinney, K., Ternier, A., Sell, J., Kahn, R., Kishore, N.
10.1101/2021.06.30.21259491 — Posted: 2021-07-05
Examining the Relationship between COVID-19 Vaccinations and Reported Incidence
Shacham, E., Scroggins, S., Garza, A.
10.1101/2021.06.30.21259794 — Posted: 2021-07-05
Impact of regional heterogeneity on the severity of COVID-19
Tsuzuki, S., Asai, Y., Matsunaga, N., Ishioka, H., Akiyama, T., Ohmagari, N.
10.1101/2021.06.30.21259758 — Posted: 2021-07-05
Disinfection of SARS-CoV-2 using UVC reveals wavelength sensitivity contributes towards rapid virucidal activity
Mariita, R. M., Wilson Miller, A. C., Randive, R. V.
10.1101/2021.06.30.21259769 — Posted: 2021-07-05
Incidence of outbreak-associated COVID-19 cases by industry in Ontario, Canada, April 1, 2020- March 31, 2021
Buchan, S. A., Smith, P. M., Warren, C., Murti, M., Mustard, C., Kim, J., Menon, S., Brown, K. A., van Ingen, T., Smith, B. T.
10.1101/2021.06.30.21259770 — Posted: 2021-07-05
Will Vaccine-derived Protective Immunity Curtail COVID-19 Variants in the US?
Mancuso, M., Eikenberry, S., Gumel, A.
10.1101/2021.06.30.21259782 — Posted: 2021-07-05
Analysis of Feature Influence on Covid-19 Death Rate Per Country Using a Novel Orthogonalization Technique
Gonnet, G., Stewart, J., Lafleur, J., Keith, S., McLellan, M., Jiang-Gorsline, D., Snider, T.
10.1101/2021.07.02.21259929 — Posted: 2021-07-05

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).